The Shift from IVDD to IVDR
The IVDR represents a massive regulatory overhaul, replacing the older In Vitro Diagnostic Directive (IVDD 98/79/EC). Historically, the IVDD allowed over 80% of IVD devices to enter the market via manufacturer self-certification. The IVDR reversed this paradigm. Today, an estimated 80% to 85% of diagnostic devices require strict conformity assessments by an independent Notified Body, introducing a heavily scrutinized pre-market ecosystem and demanding continuous post-market surveillance.
Who Must Comply ?
IVDR compliance is a legal obligation for every economic operator involved in the European IVD lifecycle:
- Legal Manufacturers: Entities designing and labeling IVDs under their own name.
- Non-EU Manufacturers: Overseas developers who must legally appoint an EU Authorized Representative (EC REP).
- Importers & Distributors: Logistics and sales entities moving devices within the single market (see our Importer of Record service).
- Health Institutions: Hospitals and laboratories manufacturing "in-house" diagnostic tests (LDTs).
Core Compliance Pillars
Achieving compliance requires manufacturers to implement robust technical and clinical frameworks:
- Risk-Based Classification: Devices are categorized into four classes based on their risk to public health: Class A (lowest risk), Class B, Class C, and Class D (highest risk), dictated by the seven rules in Annex VIII.
- Quality Management System (QMS): Establishment of an ISO 13485:2016-aligned QMS, adapted to specific IVDR mandates.
- Performance Evaluation Report (PER): A cornerstone of IVDR, the PER demands continuous, documented evidence across three pillars: Scientific Validity, Analytical Performance, and Clinical Performance.
- UDI & EUDAMED: To guarantee supply chain traceability, products must carry Unique Device Identification (UDI) barcodes, and metadata must be registered in the central European database (EUDAMED).
- PRRC Appointment: Organizations must designate at least one Person Responsible for Regulatory Compliance (Article 15).
- Post-Market Surveillance (PMS): Active, continuous monitoring through Post-Market Performance Follow-up (PMPF) to track real-world device safety and efficacy.
The Path to CE Marking
The standard roadmap to achieving market access involves seven key steps:
- Determine device classification (Class A–D).
- Upgrade the QMS and officially appoint a PRRC.
- Compile comprehensive Technical Documentation and the PER.
- Secure a legally binding agreement with an EC REP (if based outside the EU).
- Successfully pass Notified Body audits for Class B, C, and D devices.
- Register the manufacturer and assign UDI codes in EUDAMED.
- Issue the EU Declaration of Conformity and affix the CE mark.
Business Impact & Deadlines
Failure to achieve IVDR compliance results in immediate market expulsion, product recalls, and severe financial penalties. Successful compliance unlocks unrestricted access to over 450 million European consumers and builds global clinical trust.
To prevent critical diagnostic shortages, amending regulations (like EU 2024/1860) have extended transitional deadlines for legacy devices transitioning from IVDD. Depending on the risk class, transitions extend to 2027 (Class D), 2028 (Class C), or 2029 (Class B and sterile Class A), provided specific regulatory milestones are actively met.
Related Terms:
- CE Mark: Symbol declaring product conformity with applicable EU laws.
- EC REP: Designated EU entity acting on behalf of non-EU manufacturers.
- Notified Body: Independent organization authorized by an EU member state to assess device conformity.
Need support with IVDR? Explore our compliance services, review our pricing, or contact our team. | Official resources: European Commission – Medical Devices & IVD Regulations